Mylan Inc (NASDAQ:MYL), the biggest U.S. generic-drug maker, was rejected in its bid to buy Meda AB (MEDAA), the Swedish pharmaceuticals maker valued at about $4.5 billion. Mylan Inc (NASDAQ:MYL), shares after opening at $53.00 moved to $55.30 on last trade day and at the end of the day closed at $50.63. Company price to sales ratio in past twelve months was calculated as 2.73 and price to cash ratio as 64.64. Mylan Inc (NASDAQ:MYL), showed a positiveweekly performance of 3.69%.
On April, 2, 2014, BioLife Solutions, Inc. (NASDAQ:BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues, announced that Oxford, UK and Philadelphia, PA-based Adaptimmune Ltd has adopted the Company’s CryoStor clinical grade cell freeze media for use in Adaptimmune’s current phase I/II clinical trial CT Antigen TCR-Engineered T Cells for Myeloma. BioLife Solutions Inc (NASDAQ:BLFS), shares fell 6.95% in last trading session and ended the day on $3.55. BioLife Solutions Inc (NASDAQ:BLFS), return on equity ratio is recorded as 8.60% and its return on assets is -32.80%. BioLife Solutions Inc (NASDAQ:BLFS), yearly performance is -18.20%.
Smith & Nephew plc (ADR) (NYSE:SNN)‘s stock had its “hold” rating reaffirmed by investment analysts at Berenberg Bank in a note issued to investors on Monday, AR Network reports. They currently have a GBX 920 ($15.25) target price on the stock. Smith & Nephew plc (ADR) (NYSE:SNN), shares moved down 0.01% in last trading session and was closed at $76.13, while trading in range of $ 75.95 – 76.76. Smith & Nephew plc (ADR) (NYSE:SNN), year to date (YTD) performance is 6.12%.
On April, 3, 2014, Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company) announced that it intends to offer, subject to market and other conditions, shares of its common stock in an underwritten public offering. The Company intends to use the net proceeds from this offering for funding the continued development of its most advanced product candidate, sapacitabine, in a randomized study of patients with myelodysplastic syndromes (MDS), and general corporate purposes. All of the shares in this offering are to be sold by Cyclacel. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC), weekly performance is 10.50%. On last trading day company shares ended up $3.79. Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC), distance from 50-day simple moving average (SMA50) is -0.15%. Analysts mean target Price for the company is $9.67.